Ratings Mankind Pharma Limited

Equities

MANKIND

INE634S01028

Delayed NSE India S.E. Other stock markets 07:54:33 28/06/2024 BST			5-day change	1st Jan Change
2,122 ^INR	-0.60%		-2.07%	+7.02%

06-03	Mankind Pharma Limited Receives Order from Office of Superintendent of Central Tax, Bholakpur, Telangana	CI
05-30	Advent International Receives 6-7 Bids for Bharat Serums	CI

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

With an expected P/E ratio at 46.7 and 38.77 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MANKIND PHARMA LIMITED	+7.02%	10.25B	-
ELI LILLY AND COMPANY	+55.95%	819B	C+
NOVO NORDISK A/S	+43.62%	638B	B
JOHNSON & JOHNSON	-6.98%	351B	C+
MERCK & CO., INC.	+19.08%	329B	B-
ABBVIE INC.	+9.05%	298B	C+
ASTRAZENECA PLC	+16.30%	242B	B+
ROCHE HOLDING AG	+2.41%	225B	A+
NOVARTIS AG	+12.47%	217B	B-
AMGEN INC.	+8.91%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes